- Barry L. MacLean Professor of Molecular Engineering Innovation and Enterprise, Institute for Molecular Engineering
- Professor, Committee on Immunology
Ph.D., Rice University
Our laboratory develops molecular and materials engineering approaches in immunotherapy, focused on vaccination in infectious disease and cancer and on an antigen-specific tolerance induction to protein drugs, allergens and autoimmune antigens.
Nanomaterials in adjuvant and antigen delivery
Induction of adaptive immune responses to defined protein antigens, referred to as subunit vaccination, is relatively effective in generation of humoral immunity to create neutralizing antibodies but is less effective in generating cytotoxic T lymphocytes that can kill chronically-infected cells or cancer cells. We develop protein engineering and materials engineering approaches to address this lack. We work on nanomaterials that can simultaneously carry antigen and adjuvant biomolecules to dendritic cells that are resident in the lymph nodes that drain an injection site, engineering both the anatomical and sub-cellular delivery sites so as to maximize exogenous antigen presentation on MHC I and resulting induction of CD8+ T cell responses, working in both infectious disease and cancer models. We also develop nanomaterials to carry adjuvant biomolecules into tumors to modulate the tumor immune microenvironment to shape anti-tumor immunity. We develop novel nanomaterial carriers that are in the 25-50 nm regime due to their ability to penetrate interstitial barriers after injection and the tumor vasculature after intravenous administration. Thus, we both study tumor immunophysiology and develop novel interventions with the intention to tip the balance of immunity toward an anti-tumor response.
Protein and materials engineering in tolerogenic antigen delivery
Technologies to induce antigen-specific immunological tolerance are still in their infancy but are needed to prevent immunity to many protein drugs, to reverse immunity to allergens, and to prevent and reverse immunity to autoimmune antigens. We develop protein and materials engineering approaches to deliver antigens so as to induce antigen-specific tolerance, sometimes referred to as inverse vaccination. On the one hand, we investigate basic mechanisms of peripheral tolerance, how self-antigens are cleared from apoptotic cell debris, for example, in the spleen and especially the liver, to understand the mechanisms by which the body remains establishes and maintains tolerance to ageing cells and proteins. We use that understanding to develop technological approaches by which to deliver exogenous antigens so as to induce antigen-specific tolerance, using both protein engineering methods for delivery and materials engineering approaches to target antigen to particular tolerogenic cell populations. We work in models of immunity to protein drugs (for example, proteins that are not of human origin or are congenitally lacking in the subject), to protein allergens, and to autoimmune antigens (with a focus on type 1 diabetes models).